Tiziana Life Sciences (TSLA) Develops TZLS-50 to Treat COVID-19 Patients with at Risk of Respiratory Failure

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Tiziana Life Sciences (TSLA) Develops TZLS-50 to Treat COVID-19 Patients with at Risk of Respiratory Failure

Tiziana Life Sciences (TLSA) Prices 3.33M ADS Follow-On Offering at $3/ADS

March 12, 2020 5:56 AM EDT

Tiziana Life Sciences plc (NASDAQ: TLSA) today announced the pricing of its underwritten follow-on public offering (the "Offering") of American Depositary Shares ("ADSs") on the NASDAQ Global Market. Tiziana will issue 3,333,333 ADSs (representing 16,666,665 new ordinary shares of nominal value £0.03 each in the capital of the Company ("Ordinary Shares")) at... More